Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2022

View Archived Issues

Blocking UBE2N evades oncogenic immune signaling in AML

TYK2 inhibitors described by Ennovabio (Zhejiang) Pharmaceuticals, Shanghai Ennova Biopharmaceutical

New Bruton tyrosine kinase inhibitors identified at Beijing Innocare Medical Technology

Chengdu Fanxi Biopharma discovers thyroid hormone receptor alpha/beta agonists

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent Nav1.8 channel blockers

Medshine Discovery identifies new cyclin/CDK inhibitors

RIG1 activation confers protection against SARS-CoV-2 infection in mice

Study reveals dopamine as a sleep disorders target

Targeting PTP1B enhances T cell-mediated antitumor immunity

FDA grants orphan drug designation to HT-KIT for mastocytosis

Discovery of novel MDM2 inhibitor with antitumor activity in p53 wild-type cancer models

Del-1 potentiates BCI efficacy by blockade of tumor-infiltrating neutrophils

Bright Minds' BMB-101 for Dravet syndrome completes 28-day repeat toxicity studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...